Management of Blastocystis hominis and Chilomastix mesnili on Stool Microscopy
The next step is to assess whether the patient is symptomatic—if symptomatic with gastrointestinal complaints (abdominal pain, diarrhea, flatulence) and no other pathogens identified, treat with metronidazole; if asymptomatic, no treatment is necessary.
Clinical Decision Algorithm
Step 1: Evaluate for Symptoms
Specifically ask about:
- Abdominal pain (most common symptom with Blastocystis)
- Diarrhea (acute or chronic)
- Excessive flatulence
- Nausea or distention
- Duration of symptoms (>2 weeks suggests pathogenic role)
Step 2: Rule Out Other Pathogens
The pathogenicity of both organisms remains controversial 1. Before attributing symptoms to these organisms, ensure no other bacterial, viral, or parasitic pathogens are present [@2,3@]. The guideline explicitly states: "Treatment for amebiasis or giardiasis should not be considered unless microscopic examination of fresh feces shows amebic or Giardia trophozoites, or two different antibiotics given for shigellosis have not resulted in clinical improvement" 2.
Key point: Blastocystis hominis pathogenicity is controversial, with reporting requirements noting "rare, few, many" to help determine significance 1. The presence of "many" organisms increases likelihood of clinical relevance.
Step 3: Treatment Decision
If Symptomatic (with no other pathogens):
Treat with metronidazole [@2,3@]:
- Children: 30 mg/kg/day for 5-10 days (can use 15 mg/kg/day for 5 days as alternative)
- Adults: 750 mg three times daily for 5-10 days (or 250 mg three times daily for 5 days)
Research supports this approach, showing:
- Clinical cure rates of 66.6-77.7% at day 15 with metronidazole 3
- Parasitological cure rates of 93.3-94.4% at day 30 3
- Resolution of symptoms (particularly flatulence, diarrhea, abdominal cramps) in treated patients [@14,15@]
If Asymptomatic: No treatment is indicated. Both organisms can be commensal [@11,18@].
Important Caveats
Chilomastix mesnili is generally considered non-pathogenic and commensal 4. Its presence primarily indicates fecal-oral contamination. Interestingly, it has been observed adhering to Blastocystis organisms, possibly obtaining nutrients from them 5. Treatment is rarely if ever indicated for Chilomastix alone.
Alternative therapy consideration: If metronidazole fails or is contraindicated, Saccharomyces boulardii (250 mg twice daily for 10 days) showed comparable efficacy in one pediatric study 3, though this is not guideline-based. Ciprofloxacin has been reported successful in chronic cases 6, but this is based on limited case reports.
Step 4: Follow-up
Re-examine stool at 1-2 months post-treatment to confirm parasitological cure 7. If symptoms persist despite negative follow-up stool, investigate other etiologies thoroughly.
The critical distinction: The high organism burden ("many" Blastocystis) combined with moderate Chilomastix suggests significant fecal-oral exposure. If the patient has persistent gastrointestinal symptoms lasting >2 weeks with no other identified pathogens, this warrants a therapeutic trial of metronidazole [@13,14,15@].